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Abstract 
Objective/Background: 
The National Institute of Mental Health (NIMH) Research Units on Pediatric Psychopharmacology 
(RUPP) Autism Network found an effect size of d = 1.2 in favor of risperidone on the main outcome measure 
in an 8-week double-blind, placebo-controlled trial for irritabilityin autistic disorder. This paper explores 
moderators and mediators of this effect. 
Method: 
Intention-to-treat (ITT) analyses were conducted with suspected moderators and mediators entered 
into the regression equations. MacArthur Foundation Network subgroup guidelines were followed in the 
evaluation of the results. 
Results: 
Only baseline severity moderated treatment response: Higher severity showed greater improvement 
for risperidone but not for placebo. Weight gain mediated treatment response negatively: Those who gained 
more weight improved less with risperidone and more with placebo. Compliance correlated with outcome for 
risperidone but not placebo. Higher dose correlated with worse outcome for placebo, but not risperidone. Of 
nonspecific predictors, parent education, family income, and low baseline prolactin positively predicted 
outcome; anxiety, bipolar symptoms, oppositional-defiant symptoms, stereotypy, and hyperactivity 
negatively predicted outcome. Risperidone moderated the effect of change in 5'-nucleotidase, a marker of 
zinc status, for which decrease was associated with improvement only with risperidone, not with placebo. 
Conclusion: 
The benefit–risk ratio of risperidone is better with greater symptom severity. Risperidone can be 
individually titrated to optimal dosage for excellent response in the majority of children. Weight gain is not 
necessary for risperidone benefit and may even detract from it. Socioeconomic advantage, low prolactin, and 
absence of co-morbid problems non-specifically predict better outcome. Mineral interactions with 
risperidone deserve further study. 
Introduction 
The National Institute of Mental Health (NIMH) Research Units on Pediatric 
Psychopharmacology (RUPP) Autism Network reported the intention-to-treat (ITT) analyses of an 
8-week, double-blind, placebo-controlled trial of risperidone for irritability (aggression, 
self-injury, and severe tantrums) in autistic disorder (autism) (RUPP Autism Network 2002). The 
effect size d was 1.2 in favor of risperidone on the main outcome measure, the Irritability subscale 
of the Aberrant Behavior Checklist (ABC) (Aman et al. 1985). This paper explores possible 
moderators, mediators, and other predictors of that effect. 
Moderators can be patient, family, or other contextual characteristics that predict the 
differential effects of treatment choice and thus suggest a way to match patients to treatments. The 
seminal Baron and Kenny (1986) guidelines for defining moderators specified only that an 
interaction between the suspected moderator and independent variable (in this case, treatment) 
occur. However, the MacArthur Foundation Network subgroup (Kraemer et al. 2002; Kraemer et 
al. 2008) introduced widely accepted modifications to this definition. The MacArthur guidelines 
state that to be considered a moderator, a variable must: (1) Have temporal precedence, (2) be 
independent from treatment, and (3) interact significantly with treatment in the model of analysis. 
These more stringent guidelines were adopted here as requirements for moderation. 
A mediator is a postrandomization variable that is associated with treatment and may help 
to explain the mechanism through which the independent variable is affecting the dependent 
variable. Theoretically, the treatment variable affects the mediator, which, in turn, affects the 
outcome variable (Holmbeck 1997). Given a factorial model, the MacArthur guidelines for 
mediation require: (1) The temporal precedence of treatment, (2) an association between the 
mediator and treatment (in this case, point-biserial correlation), and (3) a main effect of the 
mediator or an interaction between the mediator and treatment. Although this definition does not 
require a significant effect of treatment on outcome, the absence of such treatment effect would be 
unusual if the definition is met. 
Moderator and mediator analyses in this paper were mainly exploratory, with few a priori 
hypotheses. However, we did expect that better treatment compliance (measured via tablet count 
and medication diary) and dose would be related to the effectiveness of risperidone. 
Methods 
The design, assessment and ITT results of the RUPP Autism Network risperidone study 
have been detailed elsewhere 
Moderator na Mean (SD) Range Median Cut Point 
Age (in years) 101 8.8 (2.7) 5.1–16.9 8.2 
Sex 101 1.2 (0.4) M–F  
IQ 91 48.4 (24.4) 9–111 48 
Income 99 4.4 (2.2) 1–7 $50K 
Parent Education Level 101   College degree/not 
Ethnicity 101   Caucasian/not 
ADI-R     
Social Impairment 101 26.2 (3.4) 14–33 27 
Communication impairment 101 17.3 (17.0) 7–25 17 
Stereotypy 100 7.8 (2.7) 1–12 8 
CY-BOCS 97 15.3 (3.4) 3–20 16 
ABC (BL)     
Irritability 101 25.8 (7.3) 3–44b 25 
Stereotypic behaviors 101 9.8 (4.7) 1–21 10 
Hyperactivity 100 32.1 (9.0) 11–48 33 
CGI Severity 101 5.1 (0.70) 4–7 5 
CSI (BL)     
Inattention 101 17.1 (6.0) 1–27 18 
Hyperactivity 101 16.7 (6.1) 2–27 17 
Conduct 101 4.3 (4.5) 0–16 3 
Oppositional 101 10.0 (5.6) 1–22 10 
Enuresis 101 1.9 (2.1) 0–6 1 
Encopresis 101 0.8 (1.1) 0–3 0 
Anxiety 101 14.4 (8.0) 0–42 13 
Anorexia 98 0.8 (1.6) 0–7 0 
Bulimia 99 1.1 (1.7) 0–9 0 
Depression 97 3.1 (4.0) 0–24 2 
Bipolar disorder 98 7.3 (5.9) 0–24 6 
Leptin (ng/mL) 100 5.6 (5.7) 1.0–36.7 3.4 
Prolactin (ng/mL) 95 10.2 (8.90) 2.3–39.6 6 
Weight (kg) 96 35.2 (18.7) 16.1–35.2 30 
Ferritin (ng/mL) 60 25.0 (21.6) 0.5–116.8 20.9 
Ceruloplasmin (U/L) 55 162.3 (82.7) 34.0–393.0 150.0 
CeruloplasminRID (mg/L) 57 334.0 (157.3) 97.0–875.0 328.0 
Serum zinc (μg/dL) 60 162.7 (58.1) 48.1–291.9 164.5 
Copper ( μg/dL) 56 81.8 (18.6) 36.8–116.3 85.7 
5'-Nucleotidase (U/L) 49 5.9 (1.3) 3.7–9.2 5.8 
Serum Iron (μg/dL) 39 108.0 (73.7) 15.0–390.0 95.0 
an=101. 
bIncludes an outlier who entered the study by mistake. The range was otherwise 18–44. 
Abbreviations: IQ=Intelligence quotient; ADI-R=Autism Diagnostic Interview–Revised; 
CYBOCS=Children’s Yale-Brown Obsessive Compulsive Scale; ABC=Aberrant Behavior Checklist; 
CGI=Clinical Global Impressions; CSI=Child Symptom Inventory; BL= baseline; RID = radial 
immunodiffusion. 
Table 1. Potential Moderators of Response to Risperidone 
(McDougle et al. 2000; Arnold et al. 2000; Scahill et al. 2001; RUPP Autism Network 2002). 
Briefly, it was a double-blind comparison of risperidone (n=49) versus placebo (n=52) for 8 
weeks, with a weight-based, flexible clinical drug titration for the first 4 weeks. Participants were 
children and adolescents ages 5–17 (mean 8.8 years) with Diagnostic and Statistical Manual of 
Mental Disorders, 4th edition (DSM-IV) (American Psychiatric Association 1994) autistic disorder 
and severe irritability. Primary ITT analyses showed highly significant effects of risperidone on 
both of the primary outcome measures: The ABC Irritability subscale (57% decrease vs. 14% 
decrease) and the Clinical Global Impressions– Improvement (CGI-I) (75.5% vs. 11.5% with 
CGI-I less than 3). The effect size (Cohen d) on the ABC Irritability subscale was 1.2 at 8 weeks. 
Using the primary outcome measure of the ABC Irritability subscale score, we explored 
the effects of possible moderators and mediators. Casting a wide net, we included demographic 
characteristics, diagnostic measures, symptom severity, and exploratory laboratory analyses 
(prolactin, leptin, and mineral assays). Mineral assays were included because of reports of mineral 
abnormalities in autism, especially zinc and copper and their ratio (Faber et al. 2009) and such 
related proteins as ferritin and ceruloplasmin (Chauhan et al. 2004) and because prolactin, known 
to be increased by risperidone, has been suspected of increasing ceruloplasmin (DiSilvestro 1986). 
First, potential moderators (Table 1) and mediators (Table 2) were entered into respective 
correlation matrices to check for collinearity. By predetermination, any correlation of 0.5 or 
stronger would result in combining the variables or discarding one. Most correlations were well 
below 0.2 and nonsignificant. The exceptions were parental education and income, which were 
correlated with each other (r=0.40, p < 0.0001), and the Autism Diagnostic Interview–Revised 
(ADI-R) (Lord et al. 1994) Stereotypy subscale, which correlated both with the Children’s 
Yale-Brown Obsessive Compulsive Scale (CY-BOCS) (Scahill et al. 1997) at 0.22 (p < 0.03) and 
with the ADI-R Communication Impairment subscale at 0.27 ( p < 0.01). Because all correlations 
were below r = 0.5, all variables were considered in the analysis. 
The suspected moderators and mediators were centered according to the guidelines 
recommended by Kraemer and Blasey (2004). The ordinal moderators were centered around their 
respective medians, while the binary moderators (and treatment group) were set to —0.5 or 0.5. As 
change scores, mediators were all considered to be deviations from zero. Centering the data allows 
the effects to be evaluated at the level of the independent variable that is representative of the 
group and helps to diminish the effects of multicollinearity (Kraemer and Blasey 2004). 
Some variables presented with special considerations for data analysis. For potential 
mediators, change scores were calculated as percent change (absolute change divided by baseline 
value) for ease of comparison. For medication-related variables, dose and compliance, different 
methods were used. Dose, considered to be the prescribed dosage of risperidone, was to be 
maintained during the final 4 weeks of treatment at the child’s optimal dose. This optimal dose was 
analyzed as both absolute mg/day and mg/kg per day. Compliance was 100% less the percent of 
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